Literature DB >> 8200213

Toxicology of depot medroxyprogesterone acetate.

A Jordan1.   

Abstract

Depo-Provera (depot-medroxyprogesterone acetate or DMPA), administered either subcutaneously or intramuscularly, has undergone a thorough toxicological evaluation in a number of animal species. DMPA has been tested in short- and long-term toxicity studies in rodents, rabbits, and monkeys. It has been examined for its effects on reproduction in mice, rats, and rabbits, and for carcinogenic potential in rats, mice, beagle dogs, and rhesus monkeys. Genotoxicity tests have been performed in vitro and in vivo. This paper describes the toxicology data submitted to the US FDA in support of the New Drug Application (NDA) for Depo-Provera as well as data published in the literature. When interpreted in the light of the available pharmacokinetic information, these data demonstrate that DMPA is not significantly different from other contraceptive progestogens in its toxic and tumorigenic potential.

Entities:  

Keywords:  Americas; Animals, Laboratory; Biology; Clinical Research; Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Depo-provera--side effects; Developed Countries; Evaluation; Family Planning; Knowledge; Measurement; Medroxyprogesterone Acetate--side effects; North America; Northern America; Physiology; Product Approval; Research Methodology; Research Report; Risk Assessment; Testing; Toxicity; United States

Mesh:

Substances:

Year:  1994        PMID: 8200213     DOI: 10.1016/0010-7824(94)90037-x

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

1.  Forced degradation studies of medroxyprogesterone acetate injectable suspensions (150 mg/ml) with implementation of HPLC, mass spectrometry, and QSAR techniques.

Authors:  David Jenkins; Christopher L Harmon; Xiao Jia; Allen Kesselring; Danielle Hatcher; Katie Grayson; Jennifer Ayres
Journal:  J Pharm Biomed Anal       Date:  2020-05-05       Impact factor: 3.935

2.  Quantitation of a Novel Engineered Anti-infective Host Defense Peptide, ARV-1502: Pharmacokinetic Study of Different Doses in Rats and Dogs.

Authors:  Alexandra Brakel; Daniela Volke; Carl N Kraus; Laszlo Otvos; Ralf Hoffmann
Journal:  Front Chem       Date:  2019-11-13       Impact factor: 5.221

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.